Oric Pharmaceuticals Inc
NASDAQ:ORIC
Income Statement
Earnings Waterfall
Oric Pharmaceuticals Inc
Revenue
|
0
USD
|
Operating Expenses
|
-110.8m
USD
|
Operating Income
|
-110.8m
USD
|
Other Expenses
|
10.1m
USD
|
Net Income
|
-100.7m
USD
|
Income Statement
Oric Pharmaceuticals Inc
Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Operating Income | ||||||||||||||||||
Operating Expenses |
(29)
|
(31)
|
(36)
|
(42)
|
(49)
|
(82)
|
(91)
|
(72)
|
(79)
|
(86)
|
(85)
|
(92)
|
(92)
|
(94)
|
(98)
|
(101)
|
(111)
|
|
Selling, General & Administrative |
(6)
|
(7)
|
(9)
|
(11)
|
(13)
|
(16)
|
(19)
|
(20)
|
(22)
|
(24)
|
(25)
|
(25)
|
(25)
|
(25)
|
(24)
|
(24)
|
(26)
|
|
Research & Development |
(23)
|
(25)
|
(28)
|
(31)
|
(36)
|
(40)
|
(48)
|
(52)
|
(57)
|
(62)
|
(60)
|
(67)
|
(67)
|
(69)
|
(74)
|
(77)
|
(85)
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
(25)
|
(25)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Operating Income |
(29)
N/A
|
(31)
-10%
|
(36)
-15%
|
(42)
-15%
|
(49)
-18%
|
(82)
-65%
|
(91)
-12%
|
(72)
+21%
|
(79)
-9%
|
(86)
-9%
|
(85)
+0%
|
(92)
-8%
|
(92)
+1%
|
(94)
-3%
|
(98)
-5%
|
(101)
-3%
|
(111)
-9%
|
|
Pre-Tax Income | ||||||||||||||||||
Interest Income Expense |
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
3
|
4
|
6
|
8
|
10
|
|
Non-Reccuring Items |
0
|
0
|
0
|
(13)
|
(25)
|
0
|
0
|
(12)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Pre-Tax Income |
(27)
N/A
|
(30)
-11%
|
(35)
-17%
|
(54)
-55%
|
(74)
-37%
|
(81)
-10%
|
(91)
-12%
|
(84)
+8%
|
(79)
+7%
|
(85)
-8%
|
(85)
+1%
|
(91)
-8%
|
(89)
+2%
|
(90)
-1%
|
(93)
-3%
|
(93)
-1%
|
(101)
-8%
|
|
Net Income | ||||||||||||||||||
Income from Continuing Operations |
(27)
|
(30)
|
(35)
|
(54)
|
(74)
|
(81)
|
(91)
|
(84)
|
(79)
|
(85)
|
(85)
|
(91)
|
(89)
|
(90)
|
(93)
|
(93)
|
(101)
|
|
Net Income (Common) |
(27)
N/A
|
(30)
-11%
|
(35)
-17%
|
(54)
-55%
|
(74)
-37%
|
(81)
-10%
|
(91)
-12%
|
(84)
+8%
|
(79)
+7%
|
(85)
-8%
|
(85)
+1%
|
(91)
-8%
|
(89)
+2%
|
(90)
-1%
|
(93)
-3%
|
(93)
-1%
|
(101)
-8%
|
|
EPS (Diluted) |
-0.98
N/A
|
-0.99
-1%
|
-1.16
-17%
|
-1.77
-53%
|
-3.36
-90%
|
-2.21
+34%
|
-2.48
-12%
|
-2.15
+13%
|
-2.07
+4%
|
-2.16
-4%
|
-2.15
+0%
|
-2.31
-7%
|
-2.25
+3%
|
-1.99
+12%
|
-2.02
-2%
|
-1.62
+20%
|
-1.96
-21%
|